Latest Erectile Dysfunction News

Page 1 of 4
Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.
Logan Eniac
Logan Eniac
14 Feb 2026
EVE Health Group has officially launched Libbo™, an oral dissolving film for erectile dysfunction, alongside a new digital platform aimed at improving men’s health access and education across Australia.
Ada Torres
Ada Torres
10 Feb 2026
A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.
Logan Eniac
Logan Eniac
31 Jan 2026
EVE Health Group has transitioned from development to commercial rollout, delivering first patient prescriptions of Dyspro™ and completing initial manufacturing of Libbo™, supported by a $1.1 million capital raise.
Ada Torres
Ada Torres
30 Jan 2026
EVE Health Group has completed manufacturing and distribution setup for Libbo™, its innovative oral dissolving film for erectile dysfunction, paving the way for near-term patient access via telehealth and pharmacy channels.
Ada Torres
Ada Torres
30 Jan 2026
LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.
Ada Torres
Ada Torres
28 Jan 2026
A small-cap healthcare rally had a clear centre: distribution deals, US regulatory steps, and big cheques. Osteopore, Echo IQ and Anteris led the week, while a handful of names slipped despite solid operational updates.
Logan Eniac
Logan Eniac
25 Jan 2026
LTR Pharma has initiated dosing in its Phase II clinical trial for SPONTAN, a rapid-acting intranasal spray targeting erectile dysfunction, marking a key step toward FDA approval and commercial expansion.
Ada Torres
Ada Torres
22 Jan 2026
LTR Pharma has received regulatory clearance from the Therapeutic Goods Administration to commence its Phase II clinical trial of SPONTAN, focusing on men aged 65 and over. Patient recruitment is set to begin early next year, aiming to address a key gap in erectile dysfunction treatment.
Victor Sage
Victor Sage
10 Dec 2025
LTR Pharma has secured ethics approval for its Phase II SPONTAN clinical trial, focusing on pharmacokinetics and dosing in men aged 65 and older. Recruitment begins early 2026 with initial results expected mid-year.
Ada Torres
Ada Torres
3 Dec 2025
Orthocell Limited reports growing adoption of its Remplir™ nerve repair product in nerve-sparing prostate cancer surgeries across Australia, positioning for a significant U.S. market expansion. The company is investing in research and commercial infrastructure ahead of a medium-term U.S. launch.
Ada Torres
Ada Torres
20 Nov 2025
EVE Health Group has partnered with telehealth provider hubMed to deliver a national patient support program, enhancing care continuity for users of its women’s and men’s health products Dyspro™ and Libbo™.
Ada Torres
Ada Torres
19 Nov 2025